Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1994-12-14
1996-09-03
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514715, 514729, 560231, 568667, 568670, 568838, C07C40500, A61K 31557
Patent
active
055524346
ABSTRACT:
Compounds of the formula ##STR1## where the dotted line represents a bond or the absence of a bond, the wavy lines represent bonds which are either in cis or trans configuration; R.sub.1 represents H, or CO--R.sub.2 where R.sub.2 is lower alkyl of 1 to 6 carbons, carbocyclic aryl or heterocyclic aryl; or carbocyclic aryl or heteroaryl substituted lower alkyl group; X represents CO--NR.sub.3 R.sub.4, CH.sub.2 OH, CH.sub.2 OR.sub.5, CH.sub.2 O--COR.sub.6, and CH.sub.2 --NR.sub.3 R.sub.4, where R.sub.3 and R.sub.4 independently are H or lower alkyl, R.sub.5 is lower alkyl of 1 to 6 carbons, and R.sub.6 is lower alkyl of 1 to 6 carbons, carbocyclic aryl or heterocyclic aryl; or carbocyclic aryl or heteroaryl substituted lower alkyl group, and n is an integer between 0 and 8 are capable of lowering intraocular pressure in the eye of a mammal.
REFERENCES:
patent: 3935261 (1976-01-01), Caton
patent: 4054604 (1977-10-01), Bernady
patent: 4058564 (1977-11-01), Smith
patent: 4256745 (1981-03-01), Skuballa
patent: 4454339 (1984-06-01), Skuhalla, II
patent: 4599353 (1986-07-01), Bito
patent: 4994274 (1991-02-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5385945 (1995-01-01), Garst et al.
Bito, L. Z., Arch. Ophthalmol, 105, 1036 (1987).
Bito, L. Z., Applied Pharmacology in the Medical Treatment of Glaucomas, Drance, S. M. and Neufeld, A. H. eds., New York, Grune & Stratton, 1984 pp. 477-505).
Bito, L. Z., Biological Protection with Prostaglandins, Cohen, M. M., ed., Boca Raton Fla. CRC Press Inc., 1985, pp. 231-252.
M. S. Starr, Exp. Eye Res. 11, 170-177 (1971).
Nilsson et al., Invest, Ophthalmol. Vis. Sci. 28 (suppl), 842 (1987).
Database Biosis Biosciences Information, Service Philadephia, PA, U.S. AN=7925460, Invest. Ophthalmol, Visual Sci., vol. 32 No. 4, 1991, p. 1257, Woodward D. F., et al. "Marked Species Differences in The Pharmacology of Prostanoid Induced Ocular Hypotension".
Cohen, M. M., ed. Boca Raton Fla. CRC Press Inc., 1985, 231-252.
Siebold et al., Prodrug 5, 3 (1989).
Woodward, et al., Prostaglandin F.sub.2a Effects on Intraocular Pressure Negatively Correlate with FP-Receptor Stimulation, Investigative Ophthalmology & Visual Science, vol. 30, No. 8, Aug. 1989.
Zajacz, et al., Effect on Human Eye of Prostaglandin and a Prostaglandin Analogue Used to Induce Abortion, The Eye: Reproduction, Obstetrics and Gynecology, 4, 316 (1976).
Burk Robert M.
Garst Michael E.
Allergan
Baran Robert J.
Gerstl Robert
Szekeres Gabor L.
Voet Martin A.
LandOfFree
7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1950307